A review on toxicities of T-cell engager-based therapies in solid tumors
Etienne Bastien, Clara Vacheret, Raphael Sanchez, Francesca Lucibello, Nicolas Girard, Emanuela Romano · 2026
Read A review on toxicities of T-cell engager-based therapies in solid tumors by Etienne Bastien, Clara Vacheret, Raphael Sanchez, Francesca Lucibello, Nicolas Girard, Emanuela Romano (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13527326.txt.
Description
Etienne Bastien and co-authors review the harms of a new class of cancer drugs that link T cells to tumor cells. Their 2026 review covers solid tumors, where two such drugs have gained approval so far. One treats a rare eye cancer that has spread, and one treats small-cell lung cancer.
The most common harm is a fever-like reaction from a surge of immune signals, worst in early doses. Skin effects are also frequent with the eye cancer drug. Brain-related effects occur more with the lung cancer drug but stay mild in most cases. Step-up dosing softens early harms. The authors stress that most effects start early, follow a clear pattern, and fade with care.
Catalog record
| CREATOR | Etienne Bastien, Clara Vacheret, Raphael Sanchez, Francesca Lucibello, Nicolas Girard, Emanuela Romano |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |